Cancer Marketing Expert joins TruScreen Board

NZX and Media Release 1 June 2018
NZX Limited
WELLINGTON

Cancer Marketing Expert joins TruScreen Board

Cervical cancer technology company, TruScreen Ltd (NZAX, TRU), is pleased to announce the
appointment of Marie Ficarra as an independent director on the TruScreen board.

Ms Ficarra has a detailed knowledge of cervical cancer and various cancer screening options
having specialised in the sales and marketing of medical products and diagnostics primarily
associated with cervical cancer. Her background in government provides an insight into
health regulatory processes including the introduction of new cancer screening techniques.

Ms Ficarra has had a highly successful corporate health career having served senior
corporate roles with Hoechst Australia, Behring Medical Diagnostics and as General
Manager of Cytyc Australia and New Zealand. During her time at Cytyc Ms Ficarra was
responsible for the introduction of the Thin Prep Pap Test and generated consistently high
rates of sales growth. In addition, Ms Ficarra has held a senior advisory role to Merck Sharp
and Dome (Australia) for the introduction and reimbursement of the cervical cancer vaccine
program and served on NSW Parliamentary Committees into Health and Medical Research.

Chairman of TruScreen, Mr Robert Hunter, commented: “Ms Ficarra, who has been strongly
endorsed by our Medical Advisory Committee, is the perfect fit for TruScreen as she has
extensive knowledge regarding all aspects of cervical cancer, in particular the sales and
marketing of cancer screening techniques. She is a natural saleswoman with enormous drive
and enthusiasm and has the highest level of political, government and corporate health
connections worldwide. She will be a major asset to our company as TruScreen enters the
full-scale commercialisation of its unique real-time cancer detection device”

Ms Ficarra is ordinarily a resident of Australia and has been appointed by the current
TruScreen directors, as permitted under TruScreen’s constitution. She will hold office until
TruScreen’s 2018 Annual Meeting at which time she will offer herself for re-election by
shareholders.

ENDS
For more information visit www.TruScreen.com or contact:
Martin Dillon
TruScreen Chief Executive Officer
Email: martindillon@TruScreen.com
Media Liaison
Jackie Ellis
Email: jackie@ellisandco.co.nz
Phone: +64 27 246 2505

About TruScreen:
TruScreen’s real time cervical cancer technology
utilises a digital wand which is placed on the
surface of the cervix to measure electrical and
optical signals from the surrounding tissue. A
sophisticated proprietary algorithm framework
distinguishes between normal and abnormal
(cancerous and precancerous) tissue to identify
precancerous change, or cervical intraepithelial
neoplasia (CIN). A Single Use Sensor (SUS) is used
for each patient to protect against cross-infection.